Spreadsheet: 27b8a63e-6f23-4e47-a000-158a6fd7bcc7
Sheet: Sheet1

Summary of studies used to estimate incidence of serous ovarian cancer in BRCA1 women. | Unnamed: 1 | Unnamed: 2 | Unnamed: 3 | Unnamed: 4 | Unnamed: 5 | Unnamed: 6 | Unnamed: 7 | Unnamed: 8 | Unnamed: 9 | Unnamed: 10 | Unnamed: 11 | Unnamed: 12 | Unnamed: 13 | Unnamed: 14 | Unnamed: 15
Study # | Study Citation | Study Type | Genotype | Incidence OvCa | # at-risk patients | Woman-yrs at risk | # cancers | Mean FU (years) | % w/ BRCA1 mutations | # w/ BRCA1 mutations | Total patients | Mean age during surveillance | Mean age at enrollment | Age calculation notes | Notes
1 | Rebbeck, 2002 | Retrospective | [NAME] or 2 | 0.02257160647571606 | 292 | 2569.6 | 58 | 8.8 | 0.821917808219178 | 240 | 292 | 45.3 | 40.9 | age at enrollment + average time since enrollment (mean FU/2) | Many probably genotyped after diagnosis of ovarian cancer, so may overestimate incidence and can't be used for prevalence. Apparently prospective identification of mutations in the incidence (no prophylactic surgery) control group.  Not broken down by genotype.
2 | Kauff, 2002 | Prospective | [NAME] or 2 | 0.03597122302158273 | 72 | 139 | 5 | 1.930555555555556 | 0.6666666666666666 | 48 | 72 | 46.46527777777778 | 45.5 |  | Total Woman-Years taken from text.  Patient population overlaps extensively, but in an inadequately documented way, with Scheuer.
3 | Scheuer, 2002 | Prospective | [NAME] or 2 | 0.032 | 89 | 221 | 5 | 2.48314606741573 | 0.6695278969957081 | 156 | 233 | 48.04157303370786 | 46.8 |  | BRCA1/2 status not given for 89 studied so calculate % BRCA1 of entire study cohort; 89 followed + 144 patientsexcluded because already had PBSO for total 233; Total  Woman-Years taken from text; incidence is quoted from text "32 per 1000 Woman-Years" - discrepancy from calculated 2.3% is apparently due to the fact that the 221 Woman-Years of follow-up of women with intact ovaries was in relation to breast cancer risk.  Presumably these Woman-Years excluded women with prior mastectomy and hence lower than the number for women still at risk of ovarian cancer.   Patient population overlaps extensively, but in an inadequately documented way, with Kauff.
4 | Liede, 2002 | Prospective | BRCA1 | 0.03136200716845878 | 31 | 223.2 | 7 | 7.2 | 1 | 31 | 31 | 48.4 | 44.8 |  | 10 of 31 BRCA1 patients had PO.
5 | Finch, 2006 | Prospective | BRCA1 | 0.01366635249764373 | 911 | 2122 | 29 | 2.329308452250274 | 1 | 911 | 911 | 46.72655524733488 | 45.1 no OO; 46.3 OO |  | Total Woman-Years taken from text.
5 | Finch, 2006 | Prospective | BRCA2 | 0.00297914597815293 | 344 | 1007 | 3 | 2.927325581395349 | 0 | 0 | 344 | 47.02556381190742 | 45.1 no OO; 46.3 OO | weighted average of # patients * age at enrollment + average time since enrollment (mean FU/2) | Total Woman-Years taken from text.
Summary
4,5 |  | Prospective | BRCA1 | 0.01535050315538121 | 942 | 2345.2 | 36 | 2.489596602972399 | 1 | 942 | 942 | 46.88582220486297 | 45.54378834355828
2-5 |  | Prospective | BRCA1+BRCA1/2 | 0.01231389230941453 | 1375 | 3573.2 | 44 | 2.598690909090909 | 0.7228439763001975 | 1098 | 1519 | 46.99668662092377
1-5 |  | Prospective+Retrospective | BRCA1+BRCA1/2 | 0.01660480562609885 | 1667 | 6142.8 | 102 | 3.684943011397721 | 0.7388183324130315 | 1338 | 1811 | 46.28694416778746
Citations
1 | Rebbeck TR, [NAME], Neuhausen SL, Narod SA, Van't [NAME], et [NAME]. (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346: 1616-1622.
2 | Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, et [NAME]. (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346: 1609-1615.
3 | Scheuer L, Kauff N, Robson M, Kelly B, Barakat R, et [NAME]. (2002) Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol. 20(5):1260-8
4 | Liede A, Karlan BY, [NAME], [NAME], Kuperstein G, et [NAME]. (2002) Cancer incidence in a population of Jewish women at risk of ovarian cancer. J Clin Oncol 20: 1570-1577.
5 | Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, et [NAME]. (2006) Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. [NAME] 296: 185-192.
Notes
When mean age at entry not given separately for [NAME] and 2, they were assumed to be the same.